# A Pan-TB Regimen Targeting Host and Microbe

> **NCT05686356** · PHASE2,PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **The Aurum Institute NPC** · enrollment: 352 (estimated)

## Conditions studied

- Tuberculosis

## Interventions

- **DRUG:** Sutezolid
- **DRUG:** N-acetyl cysteine
- **DRUG:** Pretomanid
- **DRUG:** Bedaquiline
- **COMBINATION_PRODUCT:** Rifafour

## Key facts

- **NCT ID:** NCT05686356
- **Lead sponsor:** The Aurum Institute NPC
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-07-28
- **Primary completion:** 2026-01
- **Final completion:** 2026-01
- **Target enrollment:** 352 (ESTIMATED)
- **Last updated:** 2025-05-28

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05686356

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05686356, "A Pan-TB Regimen Targeting Host and Microbe". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05686356. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*